Entrada Therapeutics, Inc. TRDA

Rank #4 · Nasdaq · $0.2B market cap

⚠ Going-concern flag — the auditor (Ernst & Young LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

88.5

P/E

2.7

P/B

0.73

ROE

27.1%

Op. Margin

22.3%

Debt Ratio

40%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★★★★

Excellent

P/E 2.7x, P/B 0.73x. Ranks in the top 4% of the universe.

Profitability ★★★★☆

Excellent

ROE 27.1%. Ranks in the top 16% of the universe.

Safety ★★★★☆

Excellent

Debt ratio 40%. Ranks in the top 20% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★

Excellent

Revenue growth of 63.4% year over year. Ranks in the top 6% of the universe.

Valuation is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2021	–	$-0.0B	$-0.0B	$-0.0B	–	-22
2022	–	$-0.1B	$-0.1B	$-0.0B	–	-17
2023	$0.1B	$-0.1B	$-0.1B	$0.3B	-75.4	13
2024	$0.1B	$-0.0B	$-0.0B	$0.2B	-2.5	107
2025	$0.2B	$0.0B	$0.1B	$0.2B	22.3	40

← See the full screener